- About Us
- Nano-Social Network
- Nano Consulting
- My Account
$842,503 as part of a $12 million Series C
Harris & Harris Group, Inc., announced today that it
invested $842,503 as part of a $12 million Series C round of
financing by privately held NanoOpto Corporation
(www.nanoopto.com). First Analysis led the Series C financing and
existing equity partners Morgenthaler Ventures; U.S. Trust's
Excelsior Venture Partners III, L.L.C.; Draper Fisher Jurvetson
(DFJ) Gotham Ventures and New England Ventures; and Harris & Harris
Group all participated. Doug Jamison will represent Harris & Harris
Group on the board of NanoOpto. Harris & Harris Group originally
invested in NanoOpto in March 2002 and currently owns approximately
7.97 percent of the fully diluted equity in privately held NanoOpto.
NanoOpto is applying proprietary nano-fabrication technology to the rapid design and high-volume manufacture of nano-optic devices for optical components and systems. The company's nanometer scale optical function design capability, combined with water-based manufacturing methods, delivers optical components that are directed at increasing performance and lowering cost.
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 22 initial private equity investments have been in tiny-technology enabled companies.
Harris & Harris Group is a business development company with 17,248,845 common shares outstanding.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017